MRNA - Company ID 0001682852
The table below shows Moderna, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803.00M |
| Cost of revenue | $868.00M | $1.46B | $4.69B | $5.42B | $2.62B | $8.00M |
| Gross profit | - | - | - | - | - | - |
| R&D | $3.13B | $4.54B | $4.84B | $3.29B | $1.99B | $1.37B |
| SG&A |
Moderna, Inc. reported annual revenue of $1.94B for fiscal year 2025. That is down 39.9% from $3.24B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $108.40M (FY 2016) to $1.94B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.02B |
| $1.17B |
| $1.55B |
| $1.13B |
| $567.00M |
| $188.00M |
| Operating income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B | -$763.00M |
| Income tax | $54.00M | -$46.00M | $772.00M | $1.21B | $1.08B | $3.00M |
| Net income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B | -$747.00M |
| EPS (diluted) | -$7.26 | -$9.28 | -$12.33 | $20.12 | $28.29 | -$1.96 |